No nausea or vomiting over trial period · cancer patients
Olanzapine probably leads to higher no nausea or vomiting over trial period compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.98 [1.59, 2.47]
Studies not reported
Moderate
Participant satisfaction · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Somnolence/fatigue · cancer patients
It is very uncertain whether olanzapine changes somnolence/fatigue compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 1.33 [0.4, 4.49]
Studies not reported
Very low
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Participant preference ‐ wish to use drug in next treatment · cancer patients
Olanzapine showed no clear difference in participant preference ‐ wish to use drug in next treatment compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.43 [0.97, 2.09]
Studies not reported
Moderate
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
Olanzapine showed no clear difference in other adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 1.71 [0.99, 2.96]
Studies not reported
Low
Somnolence/fatigue · cancer patients
Olanzapine probably leads to higher somnolence/fatigue compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 2.33 [1.3, 4.18]
Studies not reported
Moderate
No nausea or vomiting over trial period · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · cancer patients
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 0.33 [0.02, 7.32]
Studies not reported
Very low
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Objective assessment (prolactin levels, ng/ml) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE/FGA (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychopathology ‐ various scales · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review